Osage University Partners

What Osage University Partners does

Osage University Partners (OUP) is a venture capital firm founded in 2009 and headquartered in Bala Cynwyd, Pennsylvania, that invests exclusively in startups commercializing technology emerging from university research labs and innovation ecosystems. The firm manages approximately $800M in assets across more than 150 portfolio companies and operates with partnerships spanning 150+ universities and research institutions in the United States and abroad. OUP invests $1-20M per company across all stages from pre-seed through crossover, with sector coverage split between technology (software, hardware, climate tech) and life sciences (therapeutics, medtech, diagnostics, research tools). Its portfolio includes 35+ companies that have reached IPO, including IonQ, Beam Therapeutics, SiFive, Sana Biotechnology, Corelight, ReCode Therapeutics, DICE Therapeutics, and Menlo Security.

OUP generates returns through conventional venture fund economics: management fees on committed or invested capital, plus carried interest from successful portfolio exits. The firm monetizes its sourcing advantage by deploying concentrated checks into university spinouts that typically face early-stage capital gaps despite having differentiated technology. In January 2026, OUP extended its business model into bespoke third-party fund management when it was named manager of the $50M Penn-BioNTech Innovative Therapeutics Seed (PxB) Fund, a partnership with the University of Pennsylvania and BioNTech targeting ~15 Penn-spun life sciences companies over a 10-year horizon. OUP also operates a related sister fund, Osage Venture Partners, providing additional capital deployment capacity outside the university-spinout thesis.

The firm's go-to-market is relationship-driven rather than product-driven: deal sourcing relies on the curated network of academic technology transfer offices, founder referrals, and industry co-investors, while limited partner and academic partner engagement is supported through an Investor Portal and an Academic Partner Portal, respectively, plus content marketing (newsletter, blog, Instagram). Distribution of capital is conducted as direct equity investment into portfolio companies, with OUP typically participating as a co-investor rather than lead in most disclosed rounds. Revenue is not publicly disclosed, and the firm does not maintain a publicly disclosed pricing or fee schedule.

Name

Osage University Partners

Legal name

Osage University Partners

Website

https://www.osageuniversitypartners.com

Company type

Private

Founded year

2009

Operating status

Operating

Short description

Osage University Partners is a venture capital firm founded in 2009 that invests $1-20M in early-stage startups commercializing university research across technology and life sciences, managing $800M across 150+ portfolio companies.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Colleges, Universities, and Professional Schools (611310)

SIC

Investment Advice (6282), Services-Management Consulting Services (8742)

akta.pro primary industry

Education / EdTech Growth Equity (FSANACAL)

Keywords

• Venture capital investing
• University technology transfer
• Early-stage startup funding
• Life sciences venture capital
• Research commercialization

Headquarters

HQ city

Bala Cynwyd

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Distribution channels1 record

Marketing channels3 records

Core offering

Osage University Partners is a venture capital firm that invests capital in early-stage startups commercializing university research, deploying $1-20M per company across pre-seed through crossover stages. The firm manages $800M across 150+ portfolio companies in technology (software, hardware, climate tech) and life science (therapeutics, medtech, diagnostics, research tools) sectors, and also manages specialized co-branded funds such as the Penn-BioNTech Innovative Therapeutics Seed Fund.

Product overview

Osage University Partners is a venture capital firm that provides investment capital and support services to startup companies emerging from university research labs and innovation ecosystems. The firm does not offer a software product platform; rather, it offers investment fund management services to limited partners and portfolio support to its portfolio companies. The company manages $800M across approximately 150+ portfolio companies with a focus on technology (software, hardware, climate tech) and life science (therapeutics, medtech, diagnostics, research tools) sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Penn-BioNTech Innovative Therapeutics Seed (PxB) Fund
• OUP Core Venture Capital Investment Portfolio

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Penn-BioNTech Innovative Therapeutics Seed FundcoreOthers · 20 January 2026OUP manages this $50M fund providing seed and Series A investments to university researchers working on therapeutics, diagnostics, digital platforms, and research tools. Expected to support around 15 companies over a 10-year period.
• University of PennsylvaniacoreStrategic or Co-development Partner · 9 January 2026OUP manages the $50M Penn-BioNTech Innovative Therapeutics Seed Fund in partnership with the University of Pennsylvania and BioNTech. The fund provides seed and Series A investments to early-stage life sciences companies spun out from Penn research.
• BioNTechcoreStrategic or Co-development Partner · 9 January 2026OUP manages the $50M Penn-BioNTech Innovative Therapeutics Seed Fund in partnership with the University of Pennsylvania and BioNTech. The fund targets early-stage life sciences companies in Pennsylvania developing therapeutics, diagnostics, digital platforms, and research tools.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• SOSV: Multi-stage VC operating vertical accelerators (including HAX for hardware, IndieBio for biotech) that often invest in university research spinouts. Comparable deep-tech and life sciences orientation.
• Flagship Pioneering: Biotech creation firm that originates and builds life sciences companies from scientific platforms. Highly comparable to OUP's therapeutic and research tools life sciences investment thesis.
• Lux Capital: Science-and-technology-focused venture firm investing in deep tech, life sciences, and university-origin startups. Highly comparable to OUP's thesis of backing university research spinouts across therapeutics, hardware, and frontier tech.
• Khosla Ventures: Deep-tech and life sciences VC investing across pre-seed to crossover stages in frontier science and technology. Overlaps significantly with OUP's stage-agnostic, science-driven investment approach.
• Innovation Endeavors: Deep-tech VC investing in AI, enterprise, and life sciences companies, many originating from university research. Comparable to OUP's tech and life sciences cross-thesis focus on academic spinouts.
• Atlas Venture: Life sciences-focused VC that builds biotech companies, often in close partnership with academic founders. Comparable to OUP's therapeutics, diagnostics, and research tools investment focus.
• ARCH Venture Partners: Long-tenured life sciences and deep-tech VC originating many of its companies from academic research. Operates in the same thesis (university spinouts, therapeutics, research tools) as OUP's life sciences focus.

Others

• Osage Venture Partners: Sister fund to OUP focused on early-stage tech (predominantly B2B SaaS) in the Mid-Atlantic. Not a direct competitor for university spinouts but related through shared Osage brand and operational history.

Broad incumbents

• Andreessen Horowitz (a16z): Large, multi-stage venture firm with bio/health and deep-tech franchises that increasingly invest in academic and frontier-tech startups. Overlaps with OUP as co-investor and competitor on rounds like Tessera Labs.

Emerging players

• 1517 Fund: Early-stage VC focused on young founders including those from universities, with thematic focus on AI, climate, and biotech. Comparable early-stage university-origin investment thesis though smaller scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/osage-university-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osage University Partners